Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this study is to test the hypothesis that LY450139 given orally will slow the decline associated with AD as compared to placebo. Because of differences in regulatory requirements across regions, this objective will be assessed using different statistical methods. In one region, one method will be considered primary and the other secondary, and this relationship will be reversed for the second region. This is discussed more fully in Section 8. Both methods will use a study endpoint sometime between 64 and 88 weeks after initiation of treatment; the precise timing for this endpoint is specified in an ethical review board (ERB) supplement to this protocol. For a complete list of primary objectives please refer to the study protocol.
Critère d'inclusion
- Alzheimers Disease